• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Traws Pharma, Inc. - Common Stock (NQ:TRAW)

1.880 +0.250 (+15.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Traws Pharma, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
May 15, 2026
From Traws Pharma, Inc.
Via GlobeNewswire
Unusual volume stocks are being observed in Monday's session. ↗
May 11, 2026
Via Chartmill
Friday's session: top gainers and losers ↗
May 08, 2026
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
May 08, 2026
Via Chartmill
Gapping stocks in Friday's session ↗
May 08, 2026
Via Chartmill
TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? ↗
January 26, 2026
Via Stocktwits
Which stocks are moving before the opening bell on Friday? ↗
May 08, 2026
Via Chartmill
News headline image
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
May 08, 2026
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
TRAWS PHARMA INC (NASDAQ:TRAW) Reports 2025 Earnings Beat Amid Dilutive $60M PIPE Financing and FDA Hold ↗
April 15, 2026
Traws Pharma reports 2025 net income but stock falls on dilutive $60M PIPE financing. Focus remains on clinical trials for its influenza and COVID-19 antiviral candidates. 
Via Chartmill
Topics Earnings
News headline image
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
April 15, 2026
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Announces Up to $60 Million Private Placement Financing
April 15, 2026
From Traws Pharma, Inc.
Via GlobeNewswire
Top stock movements in today's session. ↗
February 19, 2026
Via Chartmill
Gapping stocks in Thursday's session ↗
February 19, 2026
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
February 19, 2026
Via Chartmill
News headline image
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
February 19, 2026
From Traws Pharma, Inc.
Via GlobeNewswire
Top movers analysis in the middle of the day on 2026-01-28: top gainers and losers in today's session. ↗
January 28, 2026
Via Chartmill
News headline image
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
January 26, 2026
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
January 13, 2026
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
December 17, 2025
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
December 17, 2025
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗
November 14, 2025
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Which stocks are moving on Friday? ↗
November 14, 2025
Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
November 14, 2025
 
Via Benzinga
News headline image
Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
November 13, 2025
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
October 27, 2025
 
Via Benzinga
News headline image
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
October 14, 2025
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
October 06, 2025
From Traws Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin as Chief Financial Officer
September 25, 2025
Via Investor Brand Network
News headline image
Annovis Appoints Mark Guerin as Chief Financial Officer
September 25, 2025
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
September 17, 2025
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap